Polycystic Kidney Disease
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Patients who meet the diagnostic criteria for ADPKD as defined in the Polycystic Kidney Disease (PKD) Clinical Practice Guidelines 2020. eGFR>=16mL/min/1.73m2
Exclusion criteria
Exclusion criteria: Patients receiving kidney replacement therapy (hemodialysis, peritoneal dialysis, or post-kidney transplantation) Patients deemed unsuitable for inclusion in the study by the principal investigator for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of a >=30% decline in eGFR, a >=50% decline in eGFR, or initiation of kidney replacement therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of eGFR decline during the observation period Rate of increase in total kidney volume (TKV) Death | — |
Countries
Japan
Contacts
Tokyo Women's Medical University Division of Nephrology, Department of Internal Medicine